<DOC>
	<DOCNO>NCT02620553</DOCNO>
	<brief_summary>A dose proven drug bioavailability immune system use phase II/III primary T1DM ( type 1 diabetes ) vaccination trial ( POINT study ) genetically risk subject . Study Design Randomized , placebo-controlled , double-blind/double-masked , multi-center , dose escalation primary intervention pilot study . Accrual Objective 25 ( 3:2 randomization active control arm )</brief_summary>
	<brief_title>Primary Intervention With Mucosal Insulin</brief_title>
	<detailed_description>The objective study determine feasibility , safety bioavailability oral insulin child high genetic risk T1DM dose escalation primary intervention pilot study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Children age 2 year 7 year : Have multiplex first degree family history T1DM ( parent , parent sib , two sib ) ; Type 1 diabetes susceptible HLA DR4DQB1*0302 DR4DQB1*0304 haplotype None follow HLA DR DQB1 allele : DR 11 DR 12 DQB1*0602 DR7DQB1*0303 DR14DQB1*0503 Have sibling T1DM ; Identical descent HLA DR3/DR4DQ8 genotype diabetic sibling ; 2 . Islet autoantibody negative time recruitment . 1 . Children kind congenital acquire chronic disease potentially interfere study objective . 2 . Prior current participation another intervention trial . 3 . Chronic oral steroid use and/or chronic oral immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>7 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Autoimmune Diabetes</keyword>
</DOC>